Inherent Biosciences, Inc.
Salt Lake City, UT
- UEI
- X9LJM6ADLJV7
- CAGE
- 8BC48
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 26 N Rio Grande St #2072, Salt Lake City, UT 84101, USA
- Website
- inherentbio.com
- Founded
- 2019
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| MFB Fertility, Inc. | Boulder, CO | 339113 Surgical Appliance and Supplies Manufacturing |
| TRU Diagnostics Inc. | — | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Genedx, LLC | Gaithersburg, MD | 621511 Medical Laboratories |
| Myriad Genetics Inc. | Salt Lake City, UT | 621511 Medical Laboratories |
| Asuragen Incorporated | Austin, TX | 325413 In-Vitro Diagnostic Substance Manufacturing |
About the company
Inherent Biosciences, Inc., a for-profit corporate entity based in Salt Lake City, Utah, is a federal SBIR grant recipient developing epigenetic diagnostic tests for male infertility and associated health risks under awards from the National Institute of Child Health and Human Development (NICHD) and the National Science Foundation. The vendor operates exclusively as a prime recipient on federal grants; it holds no federal contracts, IDVs, or subcontract positions.
Inherent Biosciences' capability portfolio centers on the development and clinical validation of epigenetic diagnostic assays for non-obstructive azoospermia (NOA), the severest form of male infertility affecting approximately 40 million men globally. The vendor's work targets MSH5 epigenetic modifications and DNA mismatch-repair gene mutations linked to spermatogenic failure and elevated cancer risk. The company's three NICHD SBIR awards span Phase I through Phase II work: a Phase I award dated April 1, 2022, running through March 31, 2024, focused on developing a targeted sequencing assay and validating it in a CAP/CLIA laboratory using 200 samples from Weill Cornell Medicine; a fast-track Phase II award dated August 11, 2023, extending through March 31, 2027, advancing the test toward commercialization as a laboratory developed test (LDT); and a direct-to-Phase-II award dated September 1, 2026, valued at $1.167 million, running through August 31, 2028, under CFDA 93.865 (Child Health and Human Development Extramural Research). All work is performed at Inherent Biosciences' Salt Lake City facility. The vendor also holds one NSF award in its footprint.
The vendor concentrates entirely with NICHD within the Department of Health and Human Services (three of four awards), with NSF representing a secondary customer. Combined obligated dollars across all awards total $7.2 million. Two awards face ultimate completion inside the next twenty-four months, exposing the vendor to recompete activity on existing SBIR lines. Recent award activity remains sparse—one award per year in 2020, 2022, 2023, and 2026—reflecting the typical cadence of SBIR Phase advancement rather than portfolio growth. Inherent Biosciences collaborates with Brigham Young University's Jenkins and Hill Laboratories and Weill Cornell Medicine on grant-funded research but carries no named federal prime or subcontractor relationships outside the SBIR context.
Quick answers
Is Inherent Biosciences, Inc. registered in SAM.gov?
Yes. Inherent Biosciences, Inc.'s SAM.gov registration is active through August 26, 2027.
What is Inherent Biosciences, Inc.'s most recent federal award?
Inherent Biosciences, Inc.'s most recent federal grant award is Epigenetic diagnostic for severe spermatogenic failure and associated malignancy risks (R44HD121294), from National Institute of Child Health and Human Development (NIH), on September 1, 2026.
On GovTribe
See Inherent Biosciences, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors